Ruxolitinib (phosphate)

Ruxolitinib (phosphate)

CAT N°: 23215
Price:

From 48.00 40.80

Ruxolitinib is a potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5 nM, respectively, and is relatively less selective for JAK3 (IC50 = 322 nM).{21781} It blocks interleukin-6 (IL-6) signaling (IC50 = 281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127 nM).{21782} In primary cultures, ruxolitinib preferentially suppresses erythroid progenitor colony formation from JAK2V617F+ polycythemia vera patients (IC50 = 67 nM) versus healthy donors (IC50 > 400 nM). In a mouse model of JAK2V617F+ myeloproliferative neoplasms (MPN), 90 mg/kg ruxolitinib reduces splenomegaly, decreases circulating levels of IL-6 and TNF-?, eliminates neoplastic cells, and prolongs survival.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • ?R-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile, monophosphate
  • Correlated keywords
    • 941678-49-5 Jakafi acute Janus Activated Kinase JAK 1 2 3 IL6 TNF? INCB018424 INC424
  • Product Overview:
    Ruxolitinib is a potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5 nM, respectively, and is relatively less selective for JAK3 (IC50 = 322 nM).{21781} It blocks interleukin-6 (IL-6) signaling (IC50 = 281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127 nM).{21782} In primary cultures, ruxolitinib preferentially suppresses erythroid progenitor colony formation from JAK2V617F+ polycythemia vera patients (IC50 = 67 nM) versus healthy donors (IC50 > 400 nM). In a mouse model of JAK2V617F+ myeloproliferative neoplasms (MPN), 90 mg/kg ruxolitinib reduces splenomegaly, decreases circulating levels of IL-6 and TNF-?, eliminates neoplastic cells, and prolongs survival.

We also advise you